Case-Based Learning on Medication Continuity During Complex Hospital-to-Home Transitions

Abstract

Continuity of medication during the transition from hospital to home is a critical component of quality patient care, particularly in complex cases involving polypharmacy and comorbidities. This review explores the clinical challenges, underlying mechanisms, and evidence-based strategies to ensure safe and effective medication management during these transitions. Through a case-based learning approach, the article addresses the epidemiology, pathophysiology, and risk factors influencing medication discrepancies, and provides a comprehensive synthesis of current diagnostic, therapeutic, and guideline-driven practices. Emphasis is placed on the incorporation of recent advances, emerging technologies, and interprofessional collaboration to optimize outcomes and minimize risks associated with care transitions.

Introduction

Transitions of care, especially from hospital to home, represent a vulnerable period for patients, with medication discontinuity being a prevalent and preventable source of adverse events. Complex cases—characterized by advanced age, multiple comorbidities, and extensive pharmacotherapy—are particularly susceptible to medication errors, omissions, and duplications. Effective management of these transitions requires a multifaceted, evidence-based approach tailored to the individual patient.

Epidemiology / Disease Burden

Medication errors and discontinuity during hospital-to-home transitions are responsible for a significant proportion of adverse drug events (ADEs) and hospital readmissions. Studies indicate that up to 60% of patients experience at least one medication discrepancy post-discharge, with nearly 20% resulting in potential harm. The burden is amplified in populations with chronic diseases, cognitive impairment, or limited health literacy. The economic and clinical impact underscores the need for robust strategies to bridge the gap between inpatient and outpatient care.

Pathophysiology

Medication discontinuity arises from multifactorial pathophysiological processes, including altered pharmacokinetics and pharmacodynamics in acutely ill patients, abrupt changes in medication regimens during hospitalization, and miscommunication among healthcare providers. Renal or hepatic dysfunction, drug-drug interactions, and patient-specific genetic factors further complicate pharmacotherapy during transitions. These factors can lead to therapeutic failures, toxicity, or withdrawal syndromes, especially when high-risk medications are involved.

Risk Factors

Key risk factors for medication discontinuity include advanced age, polypharmacy, multimorbidity, cognitive deficits, limited social support, and inadequate discharge planning. High-risk medications—such as anticoagulants, insulin, and opioids—are particularly susceptible to errors. Additionally, system-level issues like fragmented electronic health records, insufficient medication reconciliation processes, and lack of standardized communication protocols exacerbate the risk.

Clinical Features

Clinical manifestations of medication discontinuity can range from mild symptoms, such as headache or gastrointestinal upset, to severe complications including hypertensive crises, arrhythmias, or acute decompensation of chronic diseases. Unexplained clinical deterioration, new or worsening symptoms, and frequent healthcare utilization post-discharge should prompt evaluation for medication-related issues. Recognition of subtle signs is crucial for early intervention.

Diagnosis

Diagnosis of medication discontinuity involves a thorough review of discharge summaries, medication lists, and patient interviews. Medication reconciliation—comparing pre-admission, inpatient, and discharge medication regimens—is a cornerstone diagnostic tool. Direct communication with community pharmacists and primary care providers enhances accuracy. Laboratory monitoring and clinical assessment are essential to detect consequences of omitted or duplicated therapies.

Treatment & Management

Management hinges on proactive medication reconciliation, patient education, and clear communication across the care continuum. Multidisciplinary teams, including pharmacists, nurses, and case managers, play a critical role in ensuring accuracy and patient understanding. Use of standardized discharge checklists, teach-back methods, and follow-up phone calls can reduce medication errors. For high-risk patients, home visits or telemedicine follow-ups may further support safe transitions.

Recent Advances / Emerging Therapies

Recent advances include the integration of electronic health records (EHR) with clinical decision support tools to flag potential discrepancies and high-risk medications. Mobile health applications and digital pill organizers facilitate real-time adherence monitoring. Pharmacogenomic profiling enables personalized medication regimens, minimizing adverse reactions. Artificial intelligence-driven platforms are emerging to predict patients at highest risk and prompt targeted interventions.

Guideline Recommendations

Current guidelines from the Joint Commission, WHO, and professional societies emphasize the importance of comprehensive medication reconciliation at every transition of care. Recommendations include engaging patients and caregivers, utilizing multidisciplinary teams, and implementing standardized communication protocols. Hospitals are encouraged to adopt EHR-based tools and measure performance metrics related to medication safety during discharge procedures.

Conclusion

Medication continuity during complex hospital-to-home transitions remains a pivotal challenge in modern healthcare, with significant implications for patient safety and outcomes. Case-based learning underscores the necessity of a systematic, evidence-based approach that incorporates multidisciplinary collaboration, advanced technology, and patient engagement. Adherence to guideline-driven practices and continuous quality improvement are essential to reducing medication errors and ensuring optimal care transitions for vulnerable patient populations.